Patents by Inventor Richa Bajpai

Richa Bajpai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
    Publication number: 20220175767
    Abstract: In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.
    Type: Application
    Filed: February 21, 2022
    Publication date: June 9, 2022
    Inventors: Malathy Shanmugam, Richa Bajpai
  • Uses of Bcl-2 Antagonists for Treating Cancer and Diagnostics Related Thereto
    Publication number: 20190328729
    Abstract: In certain embodiments, this disclosure relates to method of treating and diagnosing cancer by administering a Bcl-2 inhibitor optionally in combination with a mitochondrial complex II inhibitor. In certain embodiments, a subject is diagnosed with, exhibiting symptoms of, or at risk of cancer wherein the cancer is a hematological malignancy such as multiple myeloma, leukemia, or lymphoma.
    Type: Application
    Filed: April 26, 2019
    Publication date: October 31, 2019
    Inventors: Malathy Shanmugam, Richa Bajpai
  • METHODS OF TREATING CANCER WITH A COMBINATION OF GLUCOSE MODULATORS AND BCL-2 INHIBITORS
    Publication number: 20160113925
    Abstract: This disclosure relates to treating or preventing cancers, such as hematological malignancies, by administering a compound that binds BCL2 and one or more compounds that inhibit glucose or glutamine metabolism. In certain embodiments, the compounds that inhibit glucose metabolism are ritonavir optionally in combination with 6-diazo-5-oxo-L-norleucine or any derivative, prodrugs, or salts of these compounds. Contemplated BCL2 binding compounds are ABT-199 (venetoclax), ABT-263 (navitoclax), or ABT-737.
    Type: Application
    Filed: October 21, 2015
    Publication date: April 28, 2016
    Applicant: EMORY UNIVERSITY
    Inventors: Malathy Shanmugam, Richa Bajpai, Lawrence Boise